Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins

Abstract

The finding of this gene replacement study in LGMD2D has important implications for muscular dystrophy. Sustained gene expression was seen, but studies over longer time periods without immunotherapy will be required for design of vascular delivery gene therapy trials.